Esperion Therapeutics ESPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$105.83M-1.7% | -$104.02M+32.1% | -$153.22M-196% | ||
| $106K+1.0% | $105K-0.9% | $106K0.0% | $106K+19.1% | $89K+41.3% | ||
| $9.91M+0.4% | $9.87M-4.1% | $10.29M-6.1% | $10.96M-2.3% | $11.22M-6.4% | ||
| —— | —— | -$93.29M— | —— | —— | ||
| $189K— | $0— | $0-100% | $167K-31.6% | $244K-23.0% | ||
| -$189K— | $0— | $0+100% | -$167K+31.6% | -$244K+23.0% | ||
| —— | $0-100% | $24.93M-50.0% | $49.86M-33.3% | $74.79M-25.0% | ||
| $59.9M+65.5% | $36.18M-11.8% | $41.02M— | —— | —— | ||
| $41.53M+79.8% | $23.09M+144% | -$52.27M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
